Metropolitan Life Insurance Co. NY trimmed its holdings in Agilent Technologies Inc (NYSE:A) by 66.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,556 shares of the medical research company’s stock after selling 102,976 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Agilent Technologies were worth $3,520,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of A. BlackRock Inc. raised its holdings in shares of Agilent Technologies by 8.1% in the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after buying an additional 1,912,186 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Agilent Technologies by 325.0% in the fourth quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock worth $158,732,000 after buying an additional 1,812,500 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Agilent Technologies by 145.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock worth $115,652,000 after buying an additional 1,023,099 shares during the period. TimesSquare Capital Management LLC purchased a new stake in shares of Agilent Technologies in the third quarter worth approximately $58,550,000. Finally, Bank of Montreal Can raised its holdings in shares of Agilent Technologies by 187.3% in the fourth quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after buying an additional 483,721 shares during the period.
A has been the topic of several recent analyst reports. Barclays reiterated a “buy” rating and issued a $74.00 price target on shares of Agilent Technologies in a report on Monday, January 8th. Evercore ISI initiated coverage on Agilent Technologies in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $75.00 price objective on the stock. Robert W. Baird reissued a “buy” rating and issued a $72.00 price objective on shares of Agilent Technologies in a research note on Friday, November 24th. ValuEngine cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Finally, JPMorgan Chase & Co. increased their price objective on Agilent Technologies from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $71.27.
Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.08. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Agilent Technologies had a return on equity of 17.70% and a net margin of 4.25%. During the same quarter last year, the firm earned $0.53 EPS. equities research analysts forecast that Agilent Technologies Inc will post 2.68 earnings per share for the current fiscal year.
In related news, VP Rodney Gonsalves sold 6,825 shares of the firm’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $71.23, for a total value of $486,144.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael R. Mcmullen sold 43,703 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $70.00, for a total value of $3,059,210.00. Following the completion of the transaction, the chief executive officer now owns 302,837 shares of the company’s stock, valued at approximately $21,198,590. The disclosure for this sale can be found here. Insiders sold a total of 101,103 shares of company stock valued at $7,258,967 in the last 90 days.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/03/21/metropolitan-life-insurance-co-ny-sells-102976-shares-of-agilent-technologies-inc-a.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.